ClinicalTrials.gg
Not yet recruitingNCT07803094CVSP-SOMDUpdated Sep 3, 2026

Clinical Validation Study Protocol for SmartEyes Smart Optometry Measurement Device (Medical Device Clinical Validation Study)

An observational study in Refractive Errors, sponsored by The Hong Kong Polytechnic University. Not yet recruiting. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by The Hong Kong Polytechnic University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
6 Years to 17 Years
Sex
All
01

Study summary

This study aims to evaluate the SmartEyes smart refraction measurement device in two phases under real outpatient optometry room visits at Wuhan Children's Hospital. The first phase used a prospective, single-center, stratified paired cross-sectional clinical validation design, evaluating the consistency between SmartEyes, Topcon KR-800, and subjective refraction/post-dilation refraction results among outpatient children and adolescents without and those requiring dilation, and evaluating the repeatability of the three devices under corresponding conditions. The second phase added prospective cohort follow-up to explore the relationship between SmartEyes fine scale refractive data and axial length growth, evaluating whether these results better match or predict short-term axial growth trends than traditional 0.25D stepped objective refraction results.

Read the detailed description

This prospective, single-center, non-interventional clinical validation study is designed to systematically evaluate the clinical performance, accuracy, repeatability, and functional utility of the SmartEyes optometric measurement device in pediatric and adolescent outpatient settings.

The study enrolls pediatric and adolescent subjects presenting for routine optometric examinations, covering a diverse spectrum of refractive statuses, including myopia, hyperopia, and astigmatism. The research design is structured into distinct phases and cohorts to thoroughly assess device performance under varying physiological conditions:

Phase I (Cross-Sectional Evaluation): Subjects are allocated into two parallel subgroups based on clinical routine and requirements:

Non-Cycloplegic Subgroup: Subjects complete two independent measurements with each of the three devices (Topcon KR-800, and the SmartEyes device) within a single visit, followed by subjective refraction. Between consecutive measurements, subjects are required to leave the chin/forehead rest and reposition to verify device repeatability. SmartEyes outputs its refractive results after completing its built-in optical eye relaxation protocol.

Cycloplegic Subgroup: Subjects undergo one measurement with each of the three devices prior to cycloplegia. Following routine clinical cycloplegia/ciliary muscle paralysis and subsequent subjective refraction, subjects complete two additional independent measurements with each of the three devices to evaluate repeatability and agreement under cycloplegic conditions. (Note: No extra or study-mandated cycloplegic drugs are administered solely for research purposes).

Phase II (Follow-up Evaluation): Conducts longitudinal tracking and follow-up assessments to evaluate the ongoing stability and consistency of the measurement devices over time.

To thoroughly validate the device's diagnostic capabilities, the study focuses on primary evaluation dimensions including accuracy validation (assessing agreement of sphere, cylinder, axis, spherical equivalent, and corneal curvature via Bland-Altman analysis, ICC, and Pearson correlation), repeatability validation through consecutive independent scans, and the assessment of adaptive optical relaxation functions.

This study does not involve any investigational drugs, invasive procedures, or alterations to standard clinical care pathways. The generated data will establish robust clinical evidence supporting the device's accuracy and stability, while providing standardized datasets for the continuous optimization of artificial intelligence-driven optometric algorithms and smart assistance platforms.

02

Conditions studied

  • Refractive Errors

Browse trials for

Keywords

  • Refractometers
  • Ophthalmologic Diagnostic Techniques
  • Reproducibility of Results
  • Validation Study
  • Pediatric Optometry
03

In context

Refractive Errors

420 studies on the registry are indexed under Refractive Errors; 59 are open to participants now.

This study's planned enrollment of 200 is above the median of 150 across 108 observational studies indexed under Refractive Errors.

Browse Refractive Errors studies →

Lead sponsor

The Hong Kong Polytechnic University is the lead sponsor of 679 studies on the registry; 257 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pediatric and adolescent outpatients presenting for routine optometric examinations and refractive status evaluation at the clinical site.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 6-17 years old, no gender limit;
  2. Visiting the outpatient optometry room of Wuhan Children's Hospital, clinically required refraction examination;
  3. Ability to cooperate in completing SmartEyes, Topcon KR-800, Topcon KR-1W examinations;
  4. Able to complete reliable subjective refraction;
  5. Subjects in the mydriasis subgroup should be those who need mydriasis/cycloplegia refraction for clinical diagnosis and treatment;
  6. Those who participate in the second phase cohort must be able to complete the axial length measurement and be willing to return to complete the 3-month (and 6-month) follow-up as planned;
  7. Guardians are fully informed and sign written ;
  8. Subject children accept research notifications based on their age and understanding ability, and express agreement or no objection to participating in the research.

Exclusion criteria

Exclusion Criteria:

  1. Those unable to maintain stable fixation, unable to cooperate with desktop equipment for examination, or unable to perform reliable subjective refraction;
  2. Obvious strabismus, nystagmus, severe amblyopia, or other conditions affecting the reliability of objective/subjective refraction;
  3. Keratoconus, obviously irregular astigmatism, corneal scarring, corneal edema, or other corneal diseases that significantly affect refractive measurement;
  4. Moderate to severe cataracts, obvious lens opacity, vitreous opacity, fundus diseases, and other conditions that may affect the refraction endpoint;
  5. History of previous corneal refractive surgery or intraocular surgery;
  6. Still wearing orthokeratology lenses, RGP, or other contact lenses on the day and determined by the investigator to affect measurement results;
  7. Participants in the second phase cohort who are unable to complete follow-up, plan to undergo eye surgery in the short term, or have investigators who judge axial measurement results to be clearly unreliable will not be included in the cohort follow-up analysis;
  8. Other circumstances where the investigator determines the participant is unsuitable for this study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes

Groups and cohorts

  • No pupil dilation subgroup(Phase I)

    No pupil dilation subgroup: Subjects completed two independent tests each of Topcon KR-800 and SmartEyes smart optometry devices during the same outpatient procedure, followed by subjective refraction. Between two independent tests, subjects were asked to leave the mandibular rest/forehead rest and reposition to verify the repeatability of each device. Each SmartEyes test outputs the refraction results after completing the device's built-in optical eye relaxation process.

    Device: SmartEyes smart refraction measuring device · Device: Topcon KR800 · Diagnostic Test: Subjective refraction

  • Required pupil dilation subgroup(Phase I)

    Before pupil dilation, subjects completed one test each of Topcon KR-800, and SmartEyes devices; Then, following the routine outpatient procedures of Wuhan Children's Hospital, the clinically required pupil dilation/ciliary muscle palsy was completed, followed by subjective refraction after pupil dilation. After meeting clinical examination requirements, each of the three devices underwent two independent tests to evaluate repeatability and consistency under dilated pupil conditions. No additional mydriatic drugs were used for research purposes.

    Device: SmartEyes smart refraction measuring device · Device: Topcon KR800 · Diagnostic Test: Subjective refraction

  • Follow-up visit group (Phase II)

    Subjects may be selected from those willing to continue follow-up in the first phase, or from newly screened eligible subjects in the same outpatient setting. All cohort subjects completed baseline refraction and axial measurement, followed up at 3 months (and 6 months). To reduce the impact of inspection sequence, the first phase uses a pre-established random sequence or balanced rotation sequence for the three devices; The dilation subgroup should try to maintain the same device sequence for the same subject before and after dilation. Final subjective optometry is performed by an experienced optometrist, who must not view the results of SmartEyes, or KR-800 before recording the subjective refraction endpoint.

    Device: SmartEyes smart refraction measuring device · Device: Topcon KR800 · Diagnostic Test: Subjective refraction · Device: IOL master 700

Interventions

  • DeviceSmartEyes smart refraction measuring device

    Used to acquire objective optometric parameters, including refractive errors and corneal measurements, during the clinical evaluation and comparison protocol.

  • DeviceTopcon KR800

    Used to acquire objective optometric parameters, including refractive errors and corneal measurements, during the clinical evaluation and comparison protocol.

  • Diagnostic testSubjective refraction

    Routine refractive examination

  • DeviceIOL master 700

    FDA-certified equipment used for measuring the axial length

06

What researchers measure

Primary outcomes

  1. Refractive Measurement Agreement and Repeatability across Subgroups

    Evaluate the agreement between SmartEyes, Topcon KR-800, and subjective/cycloplegic reference refractions, as well as the independent measurement repeatability of each device, across both non-cycloplegic and cycloplegic subgroups. Assess whether the optical eye relaxation function of SmartEyes yields refractive outcomes closer to subjective and cycloplegic references than conventional objective methods.

    Time frame: Phase I clinical evaluation (completed during the baseline outpatient examination sessions)

Secondary outcomes

  1. Absolute axial length change measured by optical biometry

    Absolute change in axial length (unit: mm) measured by optical biometry device.

    Time frame: From baseline through the Phase II longitudinal follow-up period (6 months)

  2. Axial length growth rate measured by optical biometry

    Axial length monthly growth rate (unit: mm/month), derived from serial axial-length measurements obtained by optical biometry device.

    Time frame: From baseline through the Phase II longitudinal follow-up period (6 months)

  3. Correlation between fine-graded refractive change and absolute axial length change

    Pearson correlation coefficient between fine-graded spherical equivalent change (SmartEyes autorefractor, diopter) and absolute axial-length change (optical biometry, mm).

    Time frame: From baseline through the Phase II longitudinal follow-up period (6 months)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07803094
Responsible party
Sponsor
First posted
Sep 3, 2026
Start date
Aug 28, 2026 (estimated)
Primary completion
Feb 2, 2027 (estimated)
Completion
Jun 2, 2027 (estimated)
Last update
Sep 3, 2026

Study contacts

Jijing Li, MD, PhD
Contact
jijing.li@cevr.hk
027-83627088
Hong Jie, MD
principal investigator · Wuhan Children's Hospital affiliated with Tongji Medical College, Huazhong University of Science and Technology
Mingguang He
study chair · The Hong Kong Polytechnic University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion